Updates on Tafasitamab for the Treatment of DLBCL

Updates on Tafasitamab for the Treatment of DLBCL

header-info

In this video, Wojciech Jurczak, MD, PhD, Jagiellonian University, Krakow, Poland, talks on tafasitamab for the treatment of diffuse large B-cell lymphoma (DLBCL), highlighting a study which demonstrated the efficacy of patients treated with tafasitamab plus lenalidomide compared to patients treated with polatuzumab vedotin and CAR-T cell therapy.